- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hypera SA (HYPE3)
Hypera SA stock price live, this page displays BVMF HYPE3 stock exchange data. View the HYPE3 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Hypera SA real time stock price chart below.
What Is the Hypera SA Stock Price Today?
The Hypera SA stock price today is 21.51.
What Is the Stock Symbol for Hypera SA?
The stock symbol for Hypera SA is "HYPE3."
What Stock Exchange Does Hypera SA Trade On?
Hypera SA is listed and trades on the B3 stock exchange.
Is Hypera SA a Good Stock to Buy?
Determining whether Hypera SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HYPE3 quote. (ISIN: BRHYPEACNOR0)
What Is the Hypera SA Stock Price Today?
The Hypera SA stock price today is 21.51.
What Is the Stock Symbol for Hypera SA?
The stock symbol for Hypera SA is "HYPE3."
What Stock Exchange Does Hypera SA Trade On?
Hypera SA is listed and trades on the B3 stock exchange.
Is Hypera SA a Good Stock to Buy?
Determining whether Hypera SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HYPE3 quote. (ISIN: BRHYPEACNOR0)
21.51
-0.33(-1.51%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.22
21.84
52 wk Range
19.71
27.79
High dividend Yield
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.2221.84
52 wk Range
19.7127.79
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.09%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.09%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
HYPE3 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
29.17
Upside
+35.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
- HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update
- Investing.com
Pro - HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 29.17
(+35.60% Upside)
Hypera SA Earnings Call Summary for Q2/2026
- Hypera posted mixed Q2 2026 results: EPS of $0.681 beat estimates by 0.41%, but revenue of $2.33B missed forecasts by 1.69%.
- Net revenue rose 8.5% YoY to BRL 2.34B; gross margin expanded 1.7 pts to 61.8%; operating cash flow reached BRL 819M, exceeding EBITDA.
- Company to launch Semavy GLP-1 drug in Sept 2026 targeting BRL 15B market; non-hormonal menopause treatment expected early 2027.
- Net debt declined BRL 400M to BRL 5.9B (2.1x EBITDA); management targets 1.5x leverage before considering M&A or buybacks.
- CapEx remains elevated through 2026 for plant expansion; free cash flow yield of 14% and 5.21% dividend yield maintained for 11th consecutive year.
Last Updated: 08/07/2026, 11:12 PM
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
0.70 / 0.68
Revenue / Forecast
2.34B / 2.37B
Compare HYPE3 to Peers and Sector
Metrics to compare | HYPE3 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHYPE3PeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.5x | 9.2x | −0.4x | |
PEG Ratio | 0.07 | −0.26 | 0.00 | |
Price/Book | 1.0x | 1.4x | 2.6x | |
Price / LTM Sales | 1.7x | 1.5x | 3.1x | |
Upside (Analyst Target) | 34.8% | 38.4% | 47.8% | |
Fair Value Upside | Unlock | 12.9% | 6.2% | Unlock |
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Hypera (HYPE3) Stock Price Today?
The Hypera stock price today is 21.51 BRL.
What Stock Exchange Does Hypera Trade On?
Hypera is listed and trades on the B3 Stock Exchange.
What Is the Stock Symbol for Hypera?
The stock symbol for Hypera is "HYPE3."
Does Hypera Pay Dividends? What’s The Current Dividend Yield?
The Hypera dividend yield is 5.09%.
What Is the Hypera Market Cap?
As of today, Hypera market cap is 15.36B BRL.
What Is Hypera's Earnings Per Share (TTM)?
The Hypera EPS (TTM) is 2.66.
When Is the Next Hypera Earnings Date?
Hypera will release its next earnings report on Oct 27, 2026.
From a Technical Analysis Perspective, Is HYPE3 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Hypera Stock Split?
Hypera has split 2 times.
How Many Employees Does Hypera Have?
Hypera has 10564 employees.
What is the current trading status of Hypera (HYPE3)?
As of Aug 15, 2026, Hypera (HYPE3) is trading at a price of 21.51 BRL, with a previous close of 21.84 BRL. The stock has fluctuated within a day range of 21.22 BRL to 21.84 BRL, while its 52-week range spans from 19.71 BRL to 27.79 BRL.
What Is Hypera (HYPE3) Price Target According to Analysts?
The average 12-month price target for Hypera is 29.17 BRL, with a high estimate of 33 BRL and a low estimate of 24 BRL. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +35.60% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.